Related Experiment Video
Updated: Dec 12, 2025
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
First Do No Harm: A Cautious, Risk-adapted Approach to Testicular Cancer Patients
Hersh M Trivedi1, Nirmish Singla1, John Lafin1
1Department of Urology, University of Texas Southwestern Medical Center Dallas, TX.
Abstract:
Current guidelines regarding treatment for germ-cell tumors (GCTs) emphasizes cautious progression focusing on stage-specific treatments. Presented herein is the case of a 30-year-old man who, through monitoring of serum alpha-fetoprotein (AFP) levels and surveillance imaging, avoided excessive treatment. This case demonstrates how an experienced clinician, familiar with natural history of GCTs, can appropriately classify level of risk and allow a patient to preserve natural fertility. Furthermore, we highlight the potential for miRNA analysis in staging and management of GCTs. This case serves to underscore the importance of acting with caution in the pursuit of the best outcome for our patients.
Insights
This case study shows how careful monitoring of germ-cell tumors (GCTs) using serum alpha-fetoprotein (AFP) and imaging can prevent overtreatment. This approach helps preserve patient fertility and highlights potential uses for miRNA analysis in GCT management.
Area of Science:
- Oncology
- Genetics
Background:
- Current germ-cell tumor (GCT) guidelines advocate for stage-specific treatments with cautious progression.
- Overtreatment in GCT patients can lead to significant long-term morbidity, including infertility.
Purpose of the Study:
- To present a case where meticulous monitoring of serum alpha-fetoprotein (AFP) and surveillance imaging allowed a patient with GCT to avoid excessive treatment.
- To emphasize the role of clinical expertise in risk stratification for GCT management.
- To explore the potential utility of miRNA analysis in the staging and management of GCTs.
Main Methods:
- Case report of a 30-year-old male patient with GCT.
- Longitudinal monitoring of serum alpha-fetoprotein (AFP) levels.
- Serial surveillance imaging (e.g., CT scans, MRI).
- Discussion of potential miRNA biomarkers for GCT staging.
Main Results:
- The patient successfully avoided aggressive or excessive treatment through vigilant monitoring.
- Preservation of natural fertility was achieved.
- Serum AFP levels and imaging data guided treatment decisions effectively.
Conclusions:
- Experienced clinical judgment, informed by the natural history of GCTs, is crucial for optimizing patient outcomes.
- Conservative management, guided by biomarkers like AFP and imaging, can be effective in select GCT cases.
- miRNA analysis presents a promising avenue for improving GCT staging and therapeutic strategies.
